Skip to main content
OpenTrials
Completed

NCT Number: NCT03796052

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

This study will test the safety and efficacy of three topical agents containing oat kernel flour to determine how well they relieve skin dryness and itching related to cancer therapies. Participants will receive a body wash, a body cream, and an anti-itch balm to use at home for 4-6 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ichthyosis Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Infant, Newborn, Diseases Keratosis Pathological Conditions, Signs and Symptoms Pruritus Signs and Symptoms Skin Abnormalities Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Sloan-Kettering Cancer Center

New York, 10022, United States

About this study

Many patients undergoing cancer therapies experience skin reactions like dry skin, rash, redness, itchiness, and hyperpigmentation. Dry skin and itching are especially common for those undergoing chemotherapy and targeted treatments.

Skincare products containing Avena sativa (oat) kernel flour have a long history of tolerance and efficacy in treating various skin conditions involving pruritus (itching) and xerosis (dry skin), as Avena sativa (oat) kernel flour is known for its skin protectant properties and soothing effects on skin. This study will evaluate the safety and efficacy of a regimen of three topical agents containing Avena sativa (oat) kernel flour for cancer patients experiencing mild to moderate pruritus and/or xerosis.

Participants will received the products at Baseline (Visit 1) and return to the clinical site at Week 5 +/- 1 week for Visit 2. In addition, questionnaires will be completed remotely between Baseline and Visit 2.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • able to read, write, speak, and understand English
  • has signed Informed Consent including Photograph Release
  • has a prior diagnosis of a solid or hematologic tumor and either:
  • is currently undergoing therapy with a systemic agent and has completed at least 3 cycles without severe skin reactions.
  • has received therapy with a systemic agent in the past 28 days.
  • is greater than 1 year status post allogeneic hematopoietic stem cell transplantation.
  • is undergoing one or more types of cancer treatment that are commonly known to cause mild to moderate skin reactions such as rash, dryness, and/or itching
  • is diagnosed with mild to moderate skin dryness (xerosis) and/or itching (pruritus).
  • is capable of all self-care and is up and mobile at least 50% of the day
  • intends to complete the study and is willing/able to follow all study instructions.

Exclusion criteria

  • has known allergies or sensitivity to skincare products or study product ingredients.
  • has other skin conditions or diseases that the investigator thinks would interfere with the study or put the subject at higher risk (e.g. immunosuppressive diseases, skin infections, etc.)
  • has severe skin dryness, itching, or rash.
  • is undergoing radiation therapy.
  • is undergoing chemotherapy or adjuntive therapies known to commonly cause complex or severe skin reactions.
  • has uncontrolled diabetes.
  • is pregnant or planning to become pregnant during the study.
  • is participating in another study for which the participant is receiving a treatment or therapy (observational studies are okay).
  • is an employee or family member of the investigator, study site, or Sponsor.

Treatment and study plan

Avena Sativa Skincare Regimen

Other

Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)

Primary outcomes

  1. Mean Change from Baseline to Visit 2 in CTCAE Grading of Xerosis

    Time frame: Baseline to Week 5 +/- 1 week

    The investigator will evaluate subjects for overall xerosis (skin dryness) using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale. For xerosis, the scale ranges from 1 (dryness covering less 10% of body surface area and no associated erythema or pruritus) to 3 (dryness covering greater than 30% of body surface area and associated with itching; limits daily self care activities of daily living). A "0" grade will be used to document subjects with no presence of the CTCAE skin adverse event symptoms for xerosis. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  2. Mean Change from Baseline to Visit 2 in CTCAE Grading of Pruritus

    Time frame: Baseline to Week 5 +/- 1 week

    The investigator will evaluate subjects for overall pruritus (skin itching) using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale. For pruritus, the scale ranges from 1 (Mild or localized; topical intervention indicated) to 3 (widespread and constant itching; limits daily self-care activities or sleep). A "0" grade will be used to document subjects with no presence of the CTCAE skin adverse event symptoms for pruritus. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  3. Mean Change from Baseline to Visit 2 in Overall Xerosis Grading

    Time frame: Baseline to Week 5 +/- 1 week

    The investigator will evaluate subjects for overall xerosis (skin dryness) using a 0 (none) to 3 (severe) scale. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  4. Mean Change from Baseline to Visit 2 in Overall Pruritus Grading

    Time frame: Baseline to Week 5 +/- 1 week

    The investigator will question subjects for overall pruritus (skin itching) using a 0 (none) to 3 (severe) scale. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  5. Mean Change from Baseline to Visit 2 in Overall Irritation Assessment

    Time frame: Baseline to Week 5 +/- 1 week

    The investigator will evaluate subjects for overall irritation using a 0 (none) to 4 (very severe) scale. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

Secondary outcomes

  1. Frequency Distribution for Overall Tolerance at Visit 2 - Subject Rating

    Time frame: Week 5 +/- 1 week

    The subject will rate how well he/she tolerated the study regimen using the following choices: Well tolerated, tolerated, or not tolerated.

  2. Frequency Distribution for Overall Tolerance at Visit 2 - Investigator Rating

    Time frame: Week 5 +/- 1 week

    The investigator will rate how well the participant tolerated the study regimen using the following choices: Well tolerated, tolerated, or not tolerated.

  3. Mean Change from Baseline to Visit 2 in PRO-CTCAE Skin Dryness

    Time frame: Baseline to Week 5 +/- 1 week

    The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) will be completed for Skin Dryness. The question asks subjects to rate the severity of their dry skin at its worst over the last 7 days from None to Very Severe on a 5-point scale. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  4. Mean Change from Baseline to Visit 2 in PRO-CTCAE Itching

    Time frame: Baseline to Week 5 +/- 1 week

    The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) will be completed for Itching. The question asks subjects to rate the severity of their itchy skin at its worst over the last 7 days from None to Very Severe on a 5-point scale. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  5. Mean Change from Baseline to Visit 2 in Skindex-16 Global Score

    Time frame: Baseline to Week 5 +/- 1 week

    The Skindex-16 is a dermatology-specific quality of life measuring tool. (The SKINDEX contact information and permission to use: Mapi Research Trust, Lyon, France. Internet: https://eprovide.mapi-trust.org). It contains 16 questions that ask subjects to rate how often over the last 7 days they have been bothered by various skin conditions on a scale of 0 (never bothered) to 6 (always bothered). The global score is the average score for all questions and is transformed to a linear scale ranging from 0 (never bothered) to 100 (always bothered) so a higher score indicates a lower quality of life. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  6. Mean Change from Baseline to Visit 2 in Skindex-16 Emotional Subscale

    Time frame: Baseline to Week 5 +/- 1 week

    The Skindex-16 is a dermatology-specific quality of life measuring tool (The SKINDEX contact information and permission to use: Mapi Research Trust, Lyon, France. Internet: https://eprovide.mapi-trust.org). It contains 16 questions that ask subjects to rate how often over the last 7 days have they been bothered by various skin conditions on a scale of 0 (never bothered) to 6 (always bothered). The Emotional subscale looks at the average score of questions 5-11 regarding emotion; the emotional score is transformed to a linear scale ranging from 0 (never bothered) to 100 (always bothered) so a higher score indicates a lower quality of life. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  7. Mean Change from Baseline to Visit 2 in Skindex-16 Symptoms Subscale

    Time frame: Baseline to Week 5 +/- 1 week

    The Skindex-16 is a dermatology-specific quality of life measuring tool (The SKINDEX contact information and permission to use: Mapi Research Trust, Lyon, France. Internet: https://eprovide.mapi-trust.org). It contains 16 questions that ask subjects to rate how often over the last 7 days have they been bothered by various skin conditions on a scale of 0 (never bothered) to 6 (always bothered). The Symptoms subscale looks at the average score of questions 1-4 individual responses regarding symptoms; the symptoms score is transformed to a linear scale ranging from 0 (never bothered) to 100 (always bothered) so a higher score indicates a lower quality of life. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  8. Mean Change from Baseline to Visit 2 in Skindex-16 Functional Subscale

    Time frame: Baseline to Week 5 +/- 1 week

    The Skindex-16 is a dermatology-specific quality of life measuring tool (The SKINDEX contact information and permission to use: Mapi Research Trust, Lyon, France. Internet: https://eprovide.mapi-trust.org). It contains 16 questions that ask subjects to rate how often over the last 7 days have they been bothered by various skin conditions on a scale of 0 (never bothered) to 6 (always bothered). The Functional subscale looks at the average score of questions 12 - 16 regarding daily functioning; the functional score is transformed to a linear scale ranging from 0 (never bothered) to 100 (always bothered) so a higher score indicates a lower quality of life. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  9. Mean Change from Baseline to Visit 2 in Skin Moisture

    Time frame: Baseline to Week 5 +/- 1 week

    Skin moisture will be measured with a Corneometer, with values ranging from 0 (no moisture) to 120 (most moisturized) arbitrary units. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  10. Mean Change from Baseline to Visit 2 in Skin Water Loss

    Time frame: Baseline to Week 5 +/- 1 week

    The amount of water lost through the skin will be measured with a Vapometer. Higher numbers indicate more water loss. Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  11. Mean Change from Baseline to Visit 2 in Self-Assessment of Dryness

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin dryness on a scale of 1 (very dry) to 10 (skin feels moisturized). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  12. Mean Change from Baseline to Visit 2 in Self-Assessment of Flakiness

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin flakiness on a scale of 1 (flaking very apparent) to 10 (no visible flaking). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  13. Mean Change from Baseline to Visit 2 in Self-Assessment of Itchiness

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin itchiness on a scale of 1 (very itchy) to 10 (not at all itchy). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 weeks).

  14. Mean Change from Baseline to Visit 2 in Self-Assessment of Roughness

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin roughness/texture on a scale of 1 (very rough) to 10 (not at all rough). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 weeks).

  15. Mean Change from Baseline to Visit 2 in Self-Assessment of Smoothness

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin smoothness on a scale of 1 (not at all smooth) to 10 (very smooth). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  16. Mean Change from Baseline to Visit 2 in Self-Assessment of Softness

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin softness on a scale of 1 (not at all soft) to 10 (very soft). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  17. Mean Change from Baseline to Visit 2 in Self-Assessment of Comfort

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate their overall skin comfort on a scale of 1 (uncomfortable/irritated) to 10 (very comfortable/not at all irritated). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

  18. Mean Change from Baseline to Visit 2 in Self-Assessment of Overall Look/Feel

    Time frame: Baseline to Week 5 +/- 1 week

    Subjects will be asked to rate the overall look and feel of their skin on a scale of 1 (not healthy looking) to 10 (healthy looking). Baseline will be compared to the subjects' final visit (Week 5 +/- 1 week).

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer Inc. (J&JCI)

Industry

Registry information

Official study title

A Single Center, Clinical Study to Determine the Safety and Efficacy of an Avena Sativa Skincare Regimen for Therapy-Related Pruritus and Xerosis in Cancer Patients

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Jan 8, 2019
Registry last updated
Nov 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.